| Sanku S Rao, MD | |
|
330 S 5th St, Suite 301, Enid, OK 73701-5825 | |
| (580) 234-0285 | |
| (580) 234-0590 |
| Full Name | Sanku S Rao |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 55 Years |
| Location | 330 S 5th St, Enid, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992864086 | NPI | - | NPPES |
| 100014700A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 12331 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Mary's Regional Medical Center | Enid, OK | Hospital |
| Integris Bass Baptist Health Center | Enid, OK | Hospital |
| Share Medical Center | Alva, OK | Hospital |
| Entity Name | Enid Gastroenterology, Inc., P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922019793 PECOS PAC ID: 4981861986 Enrollment ID: O20120202000503 |
News Archive
A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer.
Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with advanced or metastatic colorectal cancer (IND 210). The trial is being sponsored and conducted by the NCIC Clinical Trials Group at Queen's University in Kingston, Ontario.
A new study by researchers at the University of Texas Medical Branch at Galveston is the first to show that premature aging of the placenta due to oxidative stress is the cause of many preterm births. The study appears today in the American Journal of Pathology.
Protalix BioTherapeutics, Inc., announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
Formatech, Inc is pleased to announce the launch of their new website. The redesigned site features detailed information about the variety of services Formatech offers, including: product development, lyophilization development, their signature Stability Fingerprinting® program and cGMP manufacturing capabilities to support clinical trials, to name a few. The site also provides the latest Formatech news, events, case studies and offers detailed information on their recently established Fillanthropy™ Program.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sanku S Rao, MD 330 S 5th St, Suite 301, Enid, OK 73701-5825 Ph: (580) 234-0285 | Sanku S Rao, MD 330 S 5th St, Suite 301, Enid, OK 73701-5825 Ph: (580) 234-0285 |
News Archive
A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer.
Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with advanced or metastatic colorectal cancer (IND 210). The trial is being sponsored and conducted by the NCIC Clinical Trials Group at Queen's University in Kingston, Ontario.
A new study by researchers at the University of Texas Medical Branch at Galveston is the first to show that premature aging of the placenta due to oxidative stress is the cause of many preterm births. The study appears today in the American Journal of Pathology.
Protalix BioTherapeutics, Inc., announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
Formatech, Inc is pleased to announce the launch of their new website. The redesigned site features detailed information about the variety of services Formatech offers, including: product development, lyophilization development, their signature Stability Fingerprinting® program and cGMP manufacturing capabilities to support clinical trials, to name a few. The site also provides the latest Formatech news, events, case studies and offers detailed information on their recently established Fillanthropy™ Program.
› Verified 2 days ago
Daniel Dean Washburn, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 615 E Oklahoma Ave Ste 208, Enid, OK 73701 Phone: 580-242-3090 Fax: 580-234-2090 | |
Dr. Brian D. Whitson, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 620 S Madison St, Suite 209, Enid, OK 73701 Phone: 580-213-9741 Fax: 580-213-9740 | |
Dr. Charles Lawrence Cannon, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 1218 W Willow, Ste A, Enid, OK 73703 Phone: 580-233-2176 Fax: 580-233-2179 | |
Sarah Beth Matousek-fraser, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 620 S Madison St Ste 209, Enid, OK 73701 Phone: 580-977-1864 Fax: 580-977-1865 | |
Christopher A Shearer, DO Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 915 E Garriott Rd, Suite C, Enid, OK 73701 Phone: 580-234-6425 Fax: 580-234-5176 | |
David James Shepherd Jr., MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 721 W Broadway Ave Ste D, Enid, OK 73701 Phone: 580-237-0322 Fax: 580-233-0402 | |
Sumbal Nabi, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 600 S Monroe St, Enid, OK 73701 Phone: 580-977-1950 Fax: 580-977-1949 |